ライノウイルス用ワクチンの世界市場機会分析

◆英語タイトル:MarketVIEW: Rhinovirus vaccines - Vaccine opportunity assessment
◆商品コード:VACZ60301
◆発行会社(調査会社):VacZine Analytics
◆発行日:2016年1月
◆ページ数:※お問い合わせください。
◆レポート言語:英語
◆レポート形式:PDF, Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
PDF+ExcelGBP7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.

A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development.

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

*** THIS PRODUCT IS A EXECUTIVE PRESENTATION AND ONE FORECAST MODEL

【レポートの目次】

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV066_TOC_160124.pdf

****This product is composed of one forecast model and a summary presentation

Title page
Contents
Author’s note
Executive summary
HRV vaccines commercial model: key outputs
HRV vaccines: potential value ($m) by low/base/high price to 2030
HRV vaccines: potential value ($m) by target population (base price) to 2030
HRV vaccines: potential value ($m) by region (base price) to 2030
HRV vaccines: commercial model assumptions
The role of an HRV vaccine
HRV vaccine: points to note
Target markets for HRV vaccines
Major model inputs
HRV vaccine target product profile (TPP)
Drivers and resistors for a successful HRV vaccine
Disease burden caused by common respiratory viruses
Commercial parameters of respiratory viruses vaccines
HRV: background and epidemiology
Epidemiology: overview
Epidemiology: disease burden notes
Epidemiology: data – England 2009-2012
HRV disease burden: adults hospitalization (US)
HRV disease burden: respiratory viral infections and hospitalization
HRV disease burden: infants
HRV disease burden: elderly
HRV disease burden: elderly – comparative to other viruses
HRV disease burden: elderly – COPD
HRV disease burden: elderly – risk groups
HRV disease burden: asthma exacerbations
HRV disease burden: asthma exacerbations – association
HRV disease burden: asthma exacerbations – therapies
HRV disease burden: asthma exacerbations & HRV vaccine
HRV disease burden: asthma exacerbations – unmet need
HRV disease burden: COPD exacerbations
HRV disease burden: COPD exacerbations & viral infection
HRV disease burden: COPD exacerbations & disease severity
HRV disease burden: COPD exacerbations & related costs
HRV disease burden: COPD exacerbations & treatments
HRV disease burden: COPD exacerbations & economics
HRV disease burden: COPD exacerbations & HRV vaccine
HRV vaccines: R&D pipeline
Back-up: methodology
Methodology: populations (COPD)
Methodology: populations – COPD per country
Methodology: populations – asthma
Methodology: populations – asthma prevalence
Methodology: vaccine uptake
About VacZine Analytics
Disclaimer



【レポートのキーワード】

ライノウイルス、ヒトライノウイルス、ワクチン、治療薬、市場機会、市場規模

★調査レポート[ライノウイルス用ワクチンの世界市場機会分析]販売に関する免責事項
★調査レポート[ライノウイルス用ワクチンの世界市場機会分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆